Literature DB >> 25222200

Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.

Andrew J Aschenbrenner1, David A Balota1, Chi-Shing Tse2, Anne M Fagan3, David M Holtzman3, Tammie L S Benzinger4, John C Morris3.   

Abstract

OBJECTIVE: Past studies have shown that measures of attentional control and semantic memory are sensitive markers of Alzheimer's disease (AD). The effects of established biomarkers of AD (cerebrospinal fluid tau and amyloid-beta42, positron emission tomography Pittsburgh compound-B, and apolipoprotein E [APOE] genotype) on concurrent cognitive performance in cognitively normal individuals have been mixed. The present study examined the utility of combining attentional control with semantic retrieval as a sensitive correlate of AD biomarkers and used mediation analyses to examine possible mechanisms by which the biomarkers influence cognition.
METHOD: Three hundred sixty-three participants completed a category verification task (CVT), and 113 of them concurrently underwent biomarker assessments. On each trial, participants viewed a category (e.g., "unit of time") and verified whether a subsequent target item was an exemplar of the category ("hour") or not ("clock"). Importantly, the nonmembers of the category were associatively related to the category (e.g., "clock" is not "a unit of time," but is highly related), and demanded attentional control to reject.
RESULTS: Accuracy to the foil items was the strongest discriminator between healthy aging and very mild symptomatic AD. Cerebrospinal fluid biomarkers had independent yet synergistic influence on CVT performance in cognitively healthy older adults. Furthermore, the influence of the biomarkers and APOE genotype was mediated primarily through increased levels of PIB.
CONCLUSION: The combined influence of attentional control with semantic retrieval is a marker of symptomatic AD and a sensitive correlate of established biomarkers for AD risk in cognitively healthy participants. The biomarkers influenced cognition primarily through increased levels of amyloid in the brain. (c) 2015 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25222200      PMCID: PMC4362851          DOI: 10.1037/neu0000133

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  69 in total

1.  Effects of healthy aging and early stage dementia of the Alzheimer's type on components of response time distributions in three attention tasks.

Authors:  Chi-Shing Tse; David A Balota; Melvin J Yap; Janet M Duchek; David P McCabe
Journal:  Neuropsychology       Date:  2010-05       Impact factor: 3.295

2.  Predicting conversion to dementia of the Alzheimer's type in a healthy control sample: the power of errors in Stroop color naming.

Authors:  David A Balota; Chi-Shing Tse; Keith A Hutchison; Daniel H Spieler; Janet M Duchek; John C Morris
Journal:  Psychol Aging       Date:  2010-03

3.  β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.

Authors:  K M Rodrigue; K M Kennedy; M D Devous; J R Rieck; A C Hebrank; R Diaz-Arrastia; D Mathews; D C Park
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

Review 4.  Two views of brain function.

Authors:  Marcus E Raichle
Journal:  Trends Cogn Sci       Date:  2010-03-04       Impact factor: 20.229

5.  The utility of Stroop task switching as a marker for early-stage Alzheimer's disease.

Authors:  Keith A Hutchison; David A Balota; Janet M Duchek; Janet M Ducheck
Journal:  Psychol Aging       Date:  2010-09

6.  The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.

Authors:  Niklas Mattsson; Ulf Andreasson; Staffan Persson; Hiroyuki Arai; Sat Dev Batish; Sergio Bernardini; Luisella Bocchio-Chiavetto; Marinus A Blankenstein; Maria C Carrillo; Sonia Chalbot; Els Coart; Davide Chiasserini; Neal Cutler; Gunilla Dahlfors; Stefan Duller; Anne M Fagan; Orestes Forlenza; Giovanni B Frisoni; Douglas Galasko; Daniela Galimberti; Harald Hampel; Aase Handberg; Michael T Heneka; Adrianna Z Herskovits; Sanna-Kaisa Herukka; David M Holtzman; Christian Humpel; Bradley T Hyman; Khalid Iqbal; Mathias Jucker; Stephan A Kaeser; Elmar Kaiser; Elisabeth Kapaki; Daniel Kidd; Peter Klivenyi; Cindy S Knudsen; Markus P Kummer; James Lui; Albert Lladó; Piotr Lewczuk; Qiao-Xin Li; Ralph Martins; Colin Masters; John McAuliffe; Marc Mercken; Abhay Moghekar; José Luis Molinuevo; Thomas J Montine; William Nowatzke; Richard O'Brien; Markus Otto; George P Paraskevas; Lucilla Parnetti; Ronald C Petersen; David Prvulovic; Herman P M de Reus; Robert A Rissman; Elio Scarpini; Alessandro Stefani; Hilkka Soininen; Johannes Schröder; Leslie M Shaw; Anders Skinningsrud; Brith Skrogstad; Annette Spreer; Leda Talib; Charlotte Teunissen; John Q Trojanowski; Hayrettin Tumani; Robert M Umek; Bianca Van Broeck; Hugo Vanderstichele; Laszlo Vecsei; Marcel M Verbeek; Manfred Windisch; Jing Zhang; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2011-07       Impact factor: 21.566

Review 7.  Alzheimer's disease: the challenge of the second century.

Authors:  David M Holtzman; John C Morris; Alison M Goate
Journal:  Sci Transl Med       Date:  2011-04-06       Impact factor: 17.956

8.  Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.

Authors:  Kerryn E Pike; Kathryn A Ellis; Victor L Villemagne; Norm Good; Gael Chételat; David Ames; Cassandra Szoeke; Simon M Laws; Giuseppe Verdile; Ralph N Martins; Colin L Masters; Christopher C Rowe
Journal:  Neuropsychologia       Date:  2011-04-16       Impact factor: 3.139

9.  The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis.

Authors:  Nick M Wisdom; Jennifer L Callahan; Keith A Hawkins
Journal:  Neurobiol Aging       Date:  2009-03-14       Impact factor: 4.673

10.  Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.

Authors:  Prashanthi Vemuri; Stephen D Weigand; Scott A Przybelski; David S Knopman; Glenn E Smith; John Q Trojanowski; Leslie M Shaw; Charlie S Decarli; Owen Carmichael; Matt A Bernstein; Paul S Aisen; Michael Weiner; Ronald C Petersen; Clifford R Jack
Journal:  Brain       Date:  2011-04-07       Impact factor: 13.501

View more
  18 in total

1.  Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study.

Authors:  Andrew J Aschenbrenner; David A Balota; Anne M Fagan; Janet M Duchek; Tammie L S Benzinger; John C Morris
Journal:  J Int Neuropsychol Soc       Date:  2015-09       Impact factor: 2.892

2.  Multinomial models reveal deficits of two distinct controlled retrieval processes in aging and very mild Alzheimer disease.

Authors:  Peter R Millar; David A Balota; Anthony J Bishara; Larry L Jacoby
Journal:  Mem Cognit       Date:  2018-10

3.  Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset.

Authors:  Guoqiao Wang; Dean Coble; Eric M McDade; Jason Hassenstab; Anne M Fagan; Tammie L S Benzinger; Randall J Bateman; John C Morris; Chengjie Xiong
Journal:  Alzheimers Dement       Date:  2019-02-15       Impact factor: 21.566

4.  AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure.

Authors:  Shruti Mishra; Brian A Gordon; Yi Su; Jon Christensen; Karl Friedrichsen; Kelley Jackson; Russ Hornbeck; David A Balota; Nigel J Cairns; John C Morris; Beau M Ances; Tammie L S Benzinger
Journal:  Neuroimage       Date:  2017-07-26       Impact factor: 6.556

5.  Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior.

Authors:  Anja Soldan; Corinne Pettigrew; Abhay Moghekar; Marilyn Albert
Journal:  J Int Neuropsychol Soc       Date:  2016-11       Impact factor: 2.892

6.  Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers.

Authors:  Brian A Gordon; Jeffrey M Zacks; Tyler Blazey; Tammie L S Benzinger; John C Morris; Anne M Fagan; David M Holtzman; David A Balota
Journal:  Neurobiol Aging       Date:  2015-01-29       Impact factor: 4.673

7.  Latent structure of cognitive performance in the adult children study.

Authors:  Denise Head; Samantha Allison; Nathaniel Lucena; Jason Hassenstab; John C Morris
Journal:  J Clin Exp Neuropsychol       Date:  2016-11-20       Impact factor: 2.475

8.  Process dissociation analyses of memory changes in healthy aging, preclinical, and very mild Alzheimer disease: Evidence for isolated recollection deficits.

Authors:  Peter R Millar; David A Balota; Geoffrey B Maddox; Janet M Duchek; Andrew J Aschenbrenner; Anne M Fagan; Tammie L S Benzinger; John C Morris
Journal:  Neuropsychology       Date:  2017-02-16       Impact factor: 3.295

9.  Dissociative global and local task-switching costs across younger adults, middle-aged adults, older adults, and very mild Alzheimer's disease individuals.

Authors:  Mark J Huff; David A Balota; Meredith Minear; Andrew J Aschenbrenner; Janet M Duchek
Journal:  Psychol Aging       Date:  2015-12

10.  Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease.

Authors:  Andrew J Aschenbrenner; Brian A Gordon; Anne M Fagan; Suzanne E Schindler; David A Balota; John C Morris; Jason J Hassenstab
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.